Samlyn Capital’s Pacira BioSciences PCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-372,269
Closed -$14M 146
2017
Q3
$14M Buy
+372,269
New +$15M 0.35% 80
2017
Q1
Sell
-127,000
Closed -$4.1M 158
2016
Q4
$4.1M Buy
+127,000
New +$4.24M 0.09% 108

Other funds holding PCRX

Samlyn Capital's PCRX Position: Q4 2017 in Review

Samlyn Capital sold out of Pacira BioSciences (PCRX) in Q4 2017, closing a stake of 372,269 shares — an estimated $14M sold.

Samlyn Capital first reported a position in PCRX in Q4 2016 and held it in 2 quarters. The position peaked at $14M in Q3 2017. 185 funds tracked by Wall St. Rank hold PCRX as of Q4 2017.

  • Samlyn Capital reported no remaining Pacira BioSciences position as of Q4 2017 after selling out during the quarter.
  • Samlyn Capital sold 372,269 Pacira BioSciences shares in Q4 2017, an estimated $14M.
  • Samlyn Capital first reported a position in Pacira BioSciences in Q4 2016 and held it in 2 quarters.
  • Samlyn Capital's Pacira BioSciences position peaked at $14M in Q3 2017.
  • 185 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2017.

Based on Samlyn Capital's 13F filing for Q4 2017, filed 14 Feb 2018.